Compare BLW & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLW | LYEL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.4M | 490.1M |
| IPO Year | 2003 | 2021 |
| Metric | BLW | LYEL |
|---|---|---|
| Price | $12.58 | $20.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $27.25 |
| AVG Volume (30 Days) | ★ 156.4K | 80.2K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17,438.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.06 | $0.39 |
| 52 Week High | $14.28 | $45.00 |
| Indicator | BLW | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 45.66 |
| Support Level | N/A | $16.20 |
| Resistance Level | $14.08 | $27.30 |
| Average True Range (ATR) | 0.26 | 2.02 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 42.86 | 41.28 |
Blackrock Ltd Duration Income Trust is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.